{"type":"trials","record":{"id":41704,"source_id":"clinicaltrials-gov","external_id":"NCT05735730","title":"Can the Risk for AMD be Modulated?","brief_summary":"The goal of this Cross-sectional, interventional study is to learn about whether different risk factors, as Mediterranean diet, lifestyle and concomitant medication can modulate the risk imprinted by genetics in Age-related macular degeneration (AMD). The main question it aims to answer is: How the genetic risk interacts with environmental and lifestyle factors, especially Mediterranean diet and chronic medication, in order to assess how this interplay protects or presents higher risk for the establishment or the progression of AMD. Participants: Vital Signs will be measured; Medical History, Demographics, Nutritional/lifestyle habits and Family History of AMD will be recorded; Ophthalmological Examination will be performed Genetic analysis will be performed.","overall_status":"Active Not Recruiting","phases":[],"study_type":"INTERVENTIONAL","sponsor":"Association for Innovation and Biomedical Research on Light and Image","enrollment":1800,"countries":["Portugal"],"start_date":"2023-06-26","completion_date":"2028-01-12","last_update_date":"2025-09-23","source_url":"https://clinicaltrials.gov/study/NCT05735730","editorial_summary":"A registered study indexed because it matched monitored longevity research terms. Registry status: Active Not Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"AMD_LifeGene","age_range":"55 Years","comparator":null,"organization":"Association for Innovation and Biomedical Research on Light and Image","interventions":["Blood draw"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Development of AMD — 18 months","To evaluate how diet, physical activity level, body mass index, smoking, and chronic medication correlate with the deve…","Genetically characterize the population and the presence of common and rare variants associated with AMD. — 18 months","The 10-year incidence of AMD in the inland population. — 18 months","Identify genotypic-phenotypic correlations. — 18 months"],"design_description":"NA · SINGLE GROUP · DIAGNOSTIC · NONE","source_has_results":false},"controlled_terms":["Age-Related Macular Degeneration (ARMD)","Blood draw"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct05735730","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-06-26 to 2028-01-12","comparator":null,"confidence":"structured-source","population":"ALL · 55 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.856Z","intervention":["Blood draw"],"participants":1800,"study_design":"NA · SINGLE GROUP · DIAGNOSTIC · NONE","subject_scope":"Human clinical study registration","evidence_stage":"Phase not reported","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Development of AMD — 18 months","To evaluate how diet, physical activity level, body mass index, smoking, and chronic medication correlate with the deve…","Genetically characterize the population and the presence of common and rare variants associated with AMD. — 18 months","The 10-year incidence of AMD in the inland population. — 18 months","Identify genotypic-phenotypic correlations. — 18 months"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41704","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}